US FDA approves Pfizer's drug for rare bleeding disorder | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 24, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 24, 2025
US FDA approves Pfizer's drug for rare bleeding disorder

Health

Reuters
13 October, 2024, 12:45 pm
Last modified: 13 October, 2024, 12:48 pm

Related News

  • Hundreds of coffee products recalled in US over fears of potentially deadly toxin
  • Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
  • Pfizer cuts earnings outlook on lower Covid-19 drug sales
  • Pfizer's updated Covid shot effective against 'Eris' variant in mice study
  • US FDA approves Pfizer's blood cancer therapy

US FDA approves Pfizer's drug for rare bleeding disorder

The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older

Reuters
13 October, 2024, 12:45 pm
Last modified: 13 October, 2024, 12:48 pm
 A vial and a syringe are seen in front of a displayed Pfizer logo in this illustration taken November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
A vial and a syringe are seen in front of a displayed Pfizer logo in this illustration taken November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

The US Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called haemophilia, the company said on Friday.

The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in haemophilia A or B patients aged 12 years and older.

The disorder primarily affects men and causes spontaneous and potentially severe bleeding after injuries or surgery. It impacts an estimated 33,000 men in the United States, according to government data.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Hympavzi is Pfizer's second haemophilia treatment to receive FDA approval this year after the agency greenlit its haemophilia B gene therapy Beqvez in April.

Other existing treatments include gene therapies such as those made by Australia's CSL and BioMarin Pharmaceutical.

Analysts expect sales of Hympavzi to reach $300 million by 2030, according to estimates compiled by LSEG.

"Hympavzi aims to reduce the current treatment burden by meeting an important need for these patients, including many who have required frequent, time-consuming intravenous treatment infusion regimens," said Suchitra Acharya, director of the bleeding disorders program at Cohen Children's Medical Center.

The approval was based on a late-stage study in 116 haemophilia A or B patients, where the drug showed superiority to standard-of-care treatment with a 92% reduction in bleeding episodes after 12 months.

The drug is approved for patients without antibodies that stop the production of the blood-clotting proteins called factor VIII or factor IX.

Other experimental haemophilia drugs include fitusiran by partners Sanofi and Alnylam Pharmaceuticals, and Novo Nordisk's concizumab.

Pfizer is also developing a gene therapy with Sangamo Therapeutics for the treatment of haemophilia A.

World+Biz / USA

Food and Drug Administration's (FDA) / Pfizer / Hemophilia

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • An An-24 aircraft of Angara Airlines takes off from the airport of Irkutsk, Russia, in this picture taken in April 2014. Photo: Reuters/File
    Plane with 50 aboard crashes in Russia's far east, no survivors
  • Pay Commission formed to revise salary structure of employees under National Pay Scale
    Pay Commission formed to revise salary structure of employees under National Pay Scale
  • Personnel from the Bangladesh Army and Fire Service and Civil Defence are working at the scene to rescue victims and douse the flames. Photo: TBS
    Milestone tragedy: 14 among 57 hospitalised are in ICU

MOST VIEWED

  • Photo: Collected
    Bangladeshi man jailed for life in UK for murdering wife in front of their baby
  • Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
    Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
  • Fire at Cosmo School in Mirpur on 23 July 2025. Photo: TBS
    Fire breaks out at Cosmo School in Mirpur following generator explosion
  • Representational image. File Photo: Rajib Dhar/TBS
    Debate arises as edu adviser says postponed HSC exams of 22 and 24 July will be held on same day
  • BB issues dress code for all, discourages short-sleeved or length dresses, leggings for female staff
    BB issues dress code for all, discourages short-sleeved or length dresses, leggings for female staff
  • Infographics: TBS
    Stay orders won’t shield defaulters: BB governor 

Related News

  • Hundreds of coffee products recalled in US over fears of potentially deadly toxin
  • Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
  • Pfizer cuts earnings outlook on lower Covid-19 drug sales
  • Pfizer's updated Covid shot effective against 'Eris' variant in mice study
  • US FDA approves Pfizer's blood cancer therapy

Features

Photo: Collected

24 July: More than 1400 arrested, 3 missing coordinators found

14h | Panorama
Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

1d | Panorama
Photo: Mehedi Hasan/TBS

Mourning turns into outrage as Milestone students seek truth and justice

1d | Panorama
Illustration: TBS

Uttara, Jatrabari, Savar and more: The killing fields that ran red with July martyrs’ blood

2d | Panorama

More Videos from TBS

Bangladesh Bank withdraws dress code guidelines

Bangladesh Bank withdraws dress code guidelines

52m | TBS Today
Thai-Cambodian troops clash over disputed border

Thai-Cambodian troops clash over disputed border

2h | TBS World
Former chief justice Khairul Haque detained

Former chief justice Khairul Haque detained

3h | TBS Today
Why are there renewed tensions between Iran and Israel?

Why are there renewed tensions between Iran and Israel?

3h | Others
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net